epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Lancet Diabetes Endocrinol

Lower-dose CagriSema delivers nearly 20% weight loss

November 17, 2026

card-image

Clinical takeaway: Lower-dose CagriSema could offer additional options for tailoring obesity treatment to individual response and tolerability if approved. Both doses studied produced substantial weight loss, suggesting that some patients may benefit without reaching the highest studied dose.

Different dosing options could help tailor obesity treatment to individual responses and tolerability. CagriSema combines the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide. REDEFINE 9 evaluated doses below the previously studied 2.4 mg of each component.

Previously reported topline findings showed substantial weight loss with the 1 mg/1 mg dose. The newly published results, appearing in The Lancet Diabetes & Endocrinology and also presented at ObesityWeek 2026, add findings for the 1.7 mg/1.7 mg dose and more detailed safety data.

At 68 weeks, estimated average weight loss was 19.4% with 1.7 mg of each drug and 18.6% with 1 mg of each, versus 4.6% with placebo, regardless of treatment discontinuation or additional weight-management interventions. Estimates assuming everyone stayed on treatment were approximately 21% with either dose versus 2% with placebo.

Gastrointestinal adverse events were most common and generally mild to moderate. Adverse events led to permanent discontinuation in 2.9% and 4.9% of the higher- and lower-dose groups, respectively, versus 4.9% with placebo.

The Novo Nordisk–funded, randomized phase 3b trial enrolled 309 adults without diabetes who had obesity or overweight with at least one obesity-related complication. Participants received weekly injections or placebo plus lifestyle counseling. The trial was not powered to detect differences between active doses.

The findings will inform continued development of CagriSema across doses. Novo Nordisk expects an FDA decision on the 2.4 mg/2.4 mg regimen in the fourth quarter of 2026.

“These findings add to the evidence from the REDEFINE program and have potential to inform clinical practice, where dosing is often adjusted based on individual needs and clinical judgment,” said lead author Sean Wharton, MD, of the University of Toronto.

Source: Novo Nordisk. (2026 Nov 14) Novo’s investigational CagriSema, a GLP-1 and amylin analogue, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information